Predicting immune-related side effects in cancer treatment
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
This study is looking to help cancer patients who are getting immune treatments by figuring out who might be more likely to have side effects related to their immune system, so doctors can catch and manage these issues early on to improve their overall treatment experience.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11013436 on NIH RePORTER |
What this research studies
This research focuses on understanding and predicting the immune-related adverse events (irAEs) that can occur in patients receiving immune checkpoint inhibitors (ICPis) for cancer treatment. By integrating patient-reported outcomes with T-cell receptor sequencing, the study aims to develop a risk-prediction model that identifies patients at higher risk for severe irAEs. This approach will help in early detection and management of these side effects, potentially improving treatment outcomes and quality of life for patients. The research is centered on patient experiences and aims to create a clinical tool that can be used in practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with immune checkpoint inhibitors and are at risk for experiencing severe immune-related adverse events.
Not a fit: Patients who are not receiving immune checkpoint inhibitors or those with conditions unrelated to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of side effects from cancer treatments, allowing patients to continue effective therapies without debilitating interruptions.
How similar studies have performed: Preliminary studies have shown promise in using biomarkers to predict irAEs, indicating that this approach may lead to significant advancements in patient care.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Naing, Aung — University of Tx Md Anderson Can Ctr
- Study coordinator: Naing, Aung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.